Reports Q4 revenue $45.35M, consensus $47.68M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
- Coherus Biosciences announces FDA approved UDENYCA autoinjector
- Coherus BioSciences to Present at Upcoming Investor Conferences in March
- Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
- Coherus, Junshi announce final OS results of JUPITER-02 Phase 3 trial